Sidewinder Therapeutics
sidewinderbio.com
Actively hiring
Rare Disease Therapeutics
Health Care
Biologics & Biosimilars
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Backers
2
Novartis Venture Fund, OrbiMed
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
Backed byfrom the funds' portfolios and accelerator catalogs
Novartis Venture Fund 
OrbiMed Similar startupsby what they do, their industry and backers
Mendra is a venture-backed rare-disease biopharma accelerating the development and commercialization of de-risked breakthrough therapies.
ReCode is the first genetic medicines platform to enable highly targeted delivery to organs, tissues and cells beyond the liver. Our…
Healx is a Cambridge company founded in 2014 that uses artificial intelligence to find treatments for rare diseases. Its knowledge graph…
US FDA Grants Orphan Drug and Rare Pediatric Disease Designations to GEn1E Lifesciences' Dual Signal Modulator for the Treatment of…
Targeting fundamentals of Inflammation, Autoimmunity and Fibrosis. Granite Bio develops first-in-class therapeutic antibodies depleting…
We're on a mission to fulfill the promise of genetic medicine for all patients. At Addition, we are advancing a pipeline of therapeutics to…
News
Sidewinder Therapeutics: $137 Million Raised For Bispecific ADC Cancer Therapies
Sidewinder Therapeutics, a biopharmaceutical company developing next-generation bispecific antibody-drug conjugates, announced the closing of an oversubscribed $137 million Series B financing round to advance its oncology pipeline into clinical developmen
Read more
Report
Report
Sidewinder Therapeutics Announces $137 Million Series B Financing to Advance Precision Bispecific ADCs into Clinical Development for Cancer
Read more
Report
Sidewinder Therapeutics Announces $137 Million Series B Financing to Advance Precision Bispecific ADCs into Clinical Development for Cancer
Read more
Report
Lonza's Synaffix and Sidewinder Therapeutics Announce Multi-Target License Agreement to Advance Development of Next-Generation Bispecific ADCs
Multi-target license agreement grants Sidewinder access to Lonza's clinically validated ADC platform Sidewinder's pipeline of precision bispecific ADCs combined with Lonza's clinically validated ADC platform will enable the development of first-in-class b
Read more
Report
Pro access
Upgrade to see all 8 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.